ADVERTISEMENT The use of bisphosphonates to manage bone disorders such as navicular syndrome, especially in race and performance horses, has become a recent (and controversial) topic of discussion in the equine veterinary community. Until now, no studies have been published describing the drug’s disposition in horse bones—an important consideration when assessing its side effects. A team from the University of California, Davis, (UC Davis) and the University of Kentucky recently took the first step toward describing bisphosphonates’ residence time in horses’ bones. Heather K. Knych, DVM, PhD, Dipl. ACVCP, professor of Clinical Veterinary Pharmacology at UC Davis’ K.L. Maddy Equine Analytical Pharmacology Lab, presented their findings at the 2020 American Association of Equine Practitioners’ convention, held virtually.